Publications by authors named "Shanu Modi"

Claim this Profile
T
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the Safety Profile of Trastuzumab Deruxtecan by Dose: A Pooled Analysis Across DESTINY Studies.
Yeon Hee Park, Javier Cortes, Shanu Modi, Sara A Hurvitz, Giampaolo Bianchini

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding.
Wanyi Chen, Avantika Gupta, Nicholas Mai, Sharanya Nag, Joshua S Lau, Shanu Modi

Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer.
Sophia Zelizer, Grace B Gallagher, Mithat Gonen, Chau Dang, Shanu Modi

Breast Cancer Res Treat· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges.
Stephanie M Robert, Allison Toth, Sapir Lev, Stephen G Bowden, Yao Yu, Shanu Modi

J Neurooncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study.
Shanu Modi, Suyuan Zhang, Danalyn Byng, Shannon Hunter, Alessandria Strübing

Breast Cancer Res Treat· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy.
Anthony F Yu, Chau T Dang, Chaya S Moskowitz, Akriti Mishra Meza, Patricia DeFusco, Shanu Modi

JACC CardioOncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
Naoto T Ueno, Francesco Cottone, Kyle Dunton, William Jacot, Toshinari Yamashita, Shanu Modi

Oncologist· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan.
Nicholas Mai, Miriam M Klar Lieberman, Emanuela Ferraro, Maria Bromberg, Yuan Chen, Shanu Modi

JCO Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy.
Emily S Lebow, Jordan Eichholz, Zhigang Zhang, Nicolas Toumbacaris, Brandon Imber, Shanu Modi

Adv Radiat Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study.
Shanu Modi

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
Joshua Drago, Shanu Modi

Nat Rev Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation.
Tanaya Roychowdhury, Seth W McNutt, Chiranjeevi Pasala, Hieu T Nguyen, Daniel T Thornton, Shanu Modi

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.
Nicholas Mai, Carlos H Dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Shanu Modi

NPJ Breast Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
Toshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, Naoki Niikura, Yeon Hee Park, Shanu Modi

Breast Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
Antonio Marra, Sarat Chandarlapaty, Shanu Modi

Nat Rev Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.
Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, Shawn Lucas, Maha Karnoub, Shanu Modi

Virchows Arch· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer.
Nicholas Mai, Carlos H Dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Shanu Modi

Res Sq· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani

Jpn J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation.
Seth W McNutt, Tanaya Roychowdhury, Chiranjeevi Pasala, Hieu T Nguyen, Daniel T Thornton, Shanu Modi

Res Sq· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
Antonio Marra, Sarat Chandarlapaty, Shanu Modi

Nat Rev Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Evaluation of Site-Specifically Labeled Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
Randy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, Audrey Mauguen, Ryan Min, Shanu Modi

J Nucl Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Chiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, Juber Patel, Annemarie F Shepherd, Shanu Modi

Lancet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Gail D Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T Fields, Shanu Modi

Nat Commun· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.
Nelson S Moss, Jolene M Singh, Anne S Reiner, Joshua Z Drago, Shanu Modi

NPJ Breast Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis